Table 3 ACRO clinical data

 Mean age (years ± SE)

58 ± 1.5

 Age ≥ 65 (n, %)

13 (31%)

 Age ≤ 65 (n, %)

29 (69%)

 Microadenoma (n, %)

16 (38%)

 Macroadenoma (n, %)

26 (62%)

 Extra-sellar extension (n, %)

12 (29%)

 Remission (n, %)

13 (31%)

 Active controlled disease (n, %)

28 (67%)

 Active uncontrolled disease (n, %)

1 (2%)

 Mean % IGF-1 ULN ± SE

-29 ± 4.5%

 Mean GH levels (ng/ml ± SE)^a

0.98 ± 0.1

 ∙ None (n, %)

13 (31%)

 ∙ SSA (n, %)

15 (35.7%)

 ∙ PEG (n, %)

2 (4.7%)

 ∙ DA (n, %)

1 (2.4%)

 ∙ PEG + DA (n, %)

1 (2.4%)

 ∙ SSA + DA (n, %)

4 (9.5%)

 ∙ SSA + PEG (n, %)

5 (11.9%)

 ∙ SSA + PEG + DA (n, %)

1 (2.4%)

 ∙ Surgery (n, %)

29 (69%)

 ∙ RT (n, %)

1 (2%)

 ∙ GK (n, %)

2 (5%)

 ∙ SSA (n, %)

14 (33%)

 ∙ PEG (n, %)

4 (10%)

 ∙ DA (n, %)

2 (5%)